GLP-1 Medications for Weight Loss Now Available!

There are currently 44 active clinical trials seeking participants for Overweight research studies. The states with the highest number of trials for Overweight participants are California, Texas, Florida and New York.
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
04/22/2025
Locations: CenExel iResearch, LLC, Decatur, Georgia +37 locations
Conditions: Obesity, Overweight
Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)
Recruiting
Background: Artificial sweeteners like sucralose are found in many foods and drinks. Sucralose might affect hormones and cause health changes. Objective: To see if sucralose changes how medicines are absorbed and processed, how hormones are secreted, gut bacteria, and how fat cells are metabolized. Eligibility: People ages 18-60 who: * Are black or Hispanic * Weigh more than 110 pounds * Have a body mass index of 25-40 * Do not have a condition that requires drug treatment Design: Partic... Read More
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
04/22/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy Volunteers, Overweight
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: Pinnacle Research Group, LLC, Anniston, Alabama +11 locations
Conditions: Obesity, Overweight
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Recruiting
The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/17/2025
Locations: Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Ventura, California +40 locations
Conditions: Obesity, Overweight
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Recruiting
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP, is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
04/17/2025
Locations: Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Ventura, California +44 locations
Conditions: Obesity, Overweight
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Recruiting
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona +53 locations
Conditions: Obesity, Overweight
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Recruiting
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/17/2025
Locations: The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona +51 locations
Conditions: Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Recruiting
We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D). The study will last about 56 weeks and include up to 12 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Valley Clinical Trials, Inc., Northridge, California +27 locations
Conditions: Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
Optimization of Chrononutrition to Reduce the Risk of Disease in Shift Workers
Recruiting
In this randomized controlled trial, the investigators will assess the health impacts of optimizing the timing of dietary consumption in nurses and nursing assistants who work night shifts, have a habitual eating window of 14 hours or more, and elevated weight. Participants will be randomized to one of three groups: (1) dietary monitoring, (2) dietary monitoring plus 10-hour daytime time-restricted eating (TRE), or (3) TRE with a low-glycemic snack during night shifts. The study includes a 2-wee... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/14/2025
Locations: University of California San Diego Altman Clinical and Translational Research Institute, La Jolla, California
Conditions: Night Shift Work, Time Restricted Eating, Overweight, Obesity
Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate
Recruiting
Background: At least 30% of Americans have fatty liver disease. This means that they store too much fat in the liver. At the moment lifestyle changes are the only way to treat this problem. Objective: To test how (1) a low-carbohydrate diet and (2) a supplement called nicotinamide riboside (NR) affect how a person s body uses dietary fat. Eligibility: Men aged 18 to 65 and women aged 18 to 50 who are healthy volunteers with a body mass index (height to weight ratio) of 25 or more. Adults wi... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/12/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Overweight, Obesity
Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions
Recruiting
The purpose of this pilot study is to conduct a 12-week pilot feasibility study testing usability of a reinforcement learning model (AdaptRL) in a weight loss intervention (ADAPT study). Building upon a previous just-in-time adaptive intervention (JITAI), a reinforcement learning model will generate decision rules unique to each individual that are intended to improve the tailoring of brief intervention messages (e.g., what behavior to message about, what behavior change techniques to include),... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/11/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Overweight and Obesity, Overweight, Obesity
Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity
Recruiting
The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity. The total number of weeks of the study is up to approximately 22 weeks (5.5 months).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/27/2025
Locations: Anaheim Clinical Trials, LLC, Anaheim, California
Conditions: Overweight, Obesity